Anavex’s new analy­sis of its Alzheimer’s pill shows mixed re­sults

PHILADEL­PHIA — Twen­ty months ago, the small biotech com­pa­ny Anavex an­nounced that an ex­per­i­men­tal pill for Alzheimer’s dis­ease helped slow cog­ni­tive de­cline on three com­mon …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER